Supply / Manufacturing · CIS & Central Asia · Announced 14 Oct 2026

Gen İlaç → SK-Pharmacy

Gen İlaç won its first Kazakhstan tender: SK-Pharmacy will buy its Ankara-made iloprost product İlopera for 2027, worth US$838,620, with first shipments due at the end of November 2026.

Parties: Gen İlaç (Turkey) → SK-Pharmacy (Kazakhstan)

Value
$0.8m
Territory
Kazakhstan — state procurement via SK-Pharmacy for 2027
Therapeutic area
Cardiovascular
Asset
İlopera (iloprost)
Announced
14 Oct 2026

Our analysis

Why this matters

Gen İlaç disclosed on KAP on 14 October 2026 that its product İlopera (iloprost), made at its Ankara plant, won a tender run by SK-Pharmacy, the single distributor that buys medicines for Kazakhstan's Ministry of Health. The bid was submitted by Med Service Plus under authorisation from Gen's Kazakhstan representative office. The award covers 2027 and is expected to add US$838,620 to Gen's sales. The first shipment is planned for the end of November 2026. It is Gen's first tender win in Kazakhstan.

The value is small. The significance is market entry: a Turkish specialty company now sells into Kazakhstan's centralised state purchasing, which favours suppliers that have registered products and a local presence.

The full analysis is free to read with a work email on this page.

Source: Borsa Gündem (KAP disclosure)

More deals involving Gen İlaç or SK-Pharmacy

Latest deals

All CIS & Central Asia deals → · All supply / manufacturing deals → · Browse all emerging-market pharma deals →